Latest progress in marketing and R&D of margetuximab in 2025

As of2025, margetuximab (Margetuximab) has been officially launched in China and has been approved by the National Medical Products Administration (NMPA). The drug was introduced by Zai Lab from MacroGenics for the treatment of patients with metastatic HER2-positive breast cancer, especially for patients who have received two or more anti-HER2 treatment regimens. The launch in China provides patients with new treatment options.

The mechanism of action of margetuximab is similar to that of trastuzumab, but by optimizing the Fc segment, it enhances the antibody-dependent cell-mediated cytotoxicity (ADCC) effect, thereby improving the killing ability of HER2-positive tumor cells. In the global III phase SOPHIA study, the margetuximab combined with chemotherapy group had a median progression-free survival (PFS) performed better than the trastuzumab combined with chemotherapy group, showing its potential in the treatment of refractory HER2-positive breast cancer.

However, although margetuximab is already on the market in China, it has not yet been included in the national medical insurance directory, and patients need to bear higher costs when purchasing the drug. Currently, there are no generic versions of this drug on the market, which may cause patients to face certain financial pressures. Therefore, patients should fully communicate with their doctors before using this drug to understand its indications, efficacy and possible side effects to make informed decisions.

Looking to the future, with the accumulation of more clinical data and adjustments to medical insurance policies, margetuximab is expected to be more widely used in the Chinese market. At the same time, as research and development progresses, generic versions of the drug may emerge, thereby reducing treatment costs and benefiting more patients. Patients should pay attention to relevant policy changes and maintain communication with medical institutions to obtain the latest treatment information.

Reference: https://go.drugbank.com/drugs/